Vertex Pharmaceuticals Inc
Research Vertex Pharmaceuticals Inc (VRTX) on Bullrun: valuation model: 8.6% overvalued, market cap USD 140.06B, P/E 32.2. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerVRTX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Valuation signal8.6% overvalued
- Market capUSD 140.06B
- P/E32.2
- Financial periodQ2 2026
- RevenueUSD 3.33B
- Net incomeUSD 1.10B
- Free cash flowUSD 1.01B
- Gross margin85.3%
Valuation Snapshot
Bullrun's latest valuation model marks Vertex Pharmaceuticals Inc as 8.6% overvalued; latest market cap is USD 140.06B; P/E is 32.2.
Peer valuation comparison
Latest P/E is 32.16x versus a Healthcare sector median of 24.46x (31.5% above).
Latest P/E is 32.16x versus a United States median of 24.87x (29.3% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 12.00B | USD 3.95B | USD 3.19B | 86.2% | 15.32 | USD 5.08B | USD 2.03B | USD 18.67B |
| FY2024 | USD 11.02B | -USD 535.60M | -USD 790.30M | 86.1% | -2.08 | USD 4.57B | USD 1.74B | USD 16.41B |
| FY2023 | USD 9.87B | USD 3.62B | USD 3.34B | 87.2% | 13.89 | USD 10.37B | USD 808.40M | USD 17.58B |
| FY2022 | USD 8.93B | USD 3.32B | USD 3.93B | 87.9% | 12.82 | USD 10.50B | USD 531.60M | USD 13.91B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 140.06B | 32.2 | n/a | n/a |
| 2025 | 2025-12-31 | USD 115.15B | 29.6 | n/a | n/a |
| 2024 | 2024-12-31 | USD 103.47B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 104.85B | 30.5 | n/a | n/a |
| 2022 | 2022-12-30 | USD 74.13B | 22.8 | n/a | n/a |
| 2021 | 2021-12-31 | USD 55.88B | 24.3 | n/a | n/a |
About Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older;
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Vertex Pharmaceuticals Inc overvalued or undervalued?
Bullrun's valuation model currently marks Vertex Pharmaceuticals Inc as 8.6% overvalued.
What is Vertex Pharmaceuticals Inc's market cap?
Vertex Pharmaceuticals Inc's market capitalization is USD 140.06B.
What is Vertex Pharmaceuticals Inc's P/E ratio?
Vertex Pharmaceuticals Inc's price-to-earnings (P/E) ratio is 32.2.
What does Vertex Pharmaceuticals Inc do?
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain.